(PharmaNewsWire.Com, June 28, 2019 ) Global market growth is primarily driven by the growing incidence of CVD and technological advancements in interventional cardiology devices.The global interventional cardiology devices market is expected to reach USD 20.85 Billion by 2022 from USD 14.52 Billion in 2017, at a CAGR of 7.5%
The key players in the interventional cardiology devices market include Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Terumo (Japan), Cordis (US), B. Braun (Germany), C.R. Bard (US), Biosensors (Singapore), and BIOTRONIK (Germany).
Factors such as the high degree of consolidation, the high cost of devices, and complex regulatory framework for the approval of new products may restrain the market’s growth to a certain extent.
The global interventional cardiology devices market is dominated by North America, followed by Europe. North America will continue to dominate the global market in the forecast period. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered on Japan, China, and India.
Factors such as the rising focus of major players in emerging Asia Pacific countries and government support are driving the growth of the interventional cardiology devices market in this region.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
